Source study found

Story checked

Researchers followed glucose monitor users for three years and found a possible kidney benefit (opens in a new tab)

news-medical.net · 2026-10-12

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

3 supported
3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Researchers followed glucose monitor users for three years and found a possible kidney benefit

news-medical.net · 2026-10-12

The story’s checkable claims.

Read the original story

NewsLink checks it

Mixed

Every claim we could check holds up. Three of six claims match the study. This overall rating is based only on the claims we could check. Three claims the study doesn't address.

3 supported
3 not covered

Open claim evidence

The source study

Continuous Glucose Monitoring and Long-Term Glycemic and Kidney Outcomes

JAMA Network Open · 2026Open access

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredThe study was an observational comparative effectiveness study using electronic health records from Kaiser Permanente Northern California, comparing rtCGM initiators with temporally matched non-initiators and following participants for up to 36 months.View evidenceHide evidence

As statedup to 36 months

Why this verdict

The abstract-level profile supports the observational comparative-effectiveness target-trial emulation, temporally matched/risk-set sampled noninitiators, and follow-up/censoring up to 36 months. However, the specific claim that the data were electronic health records from Kaiser Permanente Northern California is not verifiable from the supplied abstract-level profile.

Study evidence

Sustained initiation of rtCGM was associated with lower HbA1c over 36 months compared with no rtCGM initiation in a per-protocol, target-trial emulation.≈0.8 percentage point lower HbA1c at 36 months (rtCGM 7.83% vs control 8.58%; 95% CIs reported; P < .001).

Study evidence

By 36 months, rtCGM initiators had significantly lower urinary albumin-creatinine ratio (UACR) than controls.−125.3 mg/g (95% CI, −196.6 to −54.0 mg/g)

Claim 2 of 6Not coveredSustained rtCGM use was associated with rapid and persistent improvements in glycemic control, with HbA1c remaining lower in the rtCGM group throughout follow-up.View evidenceHide evidence

As statedabout 1.10 percentage points at 1 year; 0.75 percentage points at 3 years

Why this verdict

The profile supports a durable association between sustained rtCGM initiation and lower HbA1c at 36 months, approximately 0.8 percentage points lower than controls. But the story’s more specific framing of 'rapid' improvement and the stated 1-year magnitude of about 1.10 percentage points are not available in the supplied abstract-level profile, so the full claim is not verifiable at this depth.

Study evidence

Claim 3 of 6Not coveredThe authors said the observational design, discontinuation, crossover, and residual confounding limit causal interpretation, and that longer-term randomized trials are needed to confirm whether rtCGM can preserve kidney function or delay diabetic kidney disease progression.View evidenceHide evidence

Why this verdict

The profile supports the caveats about observational emulation, residual confounding, substantial discontinuation/censoring, and crossover/control CGM initiation limiting causal interpretation. However, the supplied abstract-level profile does not verify the specific statement that the authors called for longer-term randomized trials to confirm preservation of kidney function or delayed diabetic kidney disease progression. That portion may be plausible but is not verifiable from the provided profile.

Study evidence

Study evidence

By 36 months, rtCGM initiators had significantly lower urinary albumin-creatinine ratio (UACR) than controls.−125.3 mg/g (95% CI, −196.6 to −54.0 mg/g)

Claim 4 of 6SupportedIn a recent study published in JAMA Network Open, researchers evaluated the association between sustained real-time continuous glucose monitoring (rtCGM) and long-term glycemic control and kidney health markers in high-risk adults with type 2 diabetes.View evidenceHide evidence

Why this verdict

The supplied abstract-level profile supports that the paper evaluated initiation and sustained use of rtCGM versus no initiation in high-risk adults with type 2 diabetes, and that outcomes included long-term glycemic control and kidney markers. The story frames this as an association, which matches the observational target-trial emulation evidence.

Study evidence

Study evidence

By 36 months, rtCGM initiators had significantly lower urinary albumin-creatinine ratio (UACR) than controls.−125.3 mg/g (95% CI, −196.6 to −54.0 mg/g)

Claim 5 of 6SupportedAt three years, sustained rtCGM use was associated with a lower mean urinary albumin-creatinine ratio (UACR), suggesting a later reduction in albuminuria.View evidenceHide evidence

As statedabout 125 mg/g lower UACR at 3 years

Why this verdict

The abstract-level profile reports that UACR differences were not significant initially but emerged by 36 months, with rtCGM initiators having lower UACR than controls by about 125.3 mg/g. The story frames this as an association and uses cautious language about a later reduction in albuminuria, which is consistent with the profile.

Study evidence

By 36 months, rtCGM initiators had significantly lower urinary albumin-creatinine ratio (UACR) than controls.−125.3 mg/g (95% CI, −196.6 to −54.0 mg/g)

Claim 6 of 6SupportedThe study did not demonstrate preservation of kidney filtration function, as measured by eGFR, after three years.View evidenceHide evidence

As statedno statistically significant difference at 3 years

Why this verdict

The profile states that there were no differences in eGFR during follow-up. The story’s statement that the study did not demonstrate preservation of kidney filtration function as measured by eGFR is consistent with that abstract-level evidence and appropriately cautious.

Study evidence

By 36 months, rtCGM initiators had significantly lower urinary albumin-creatinine ratio (UACR) than controls.−125.3 mg/g (95% CI, −196.6 to −54.0 mg/g)

Then look for missing context

Context layer

What the story carried across

Nothing material from the study was dropped.

8 things the story did carry across

The study’s central design was an observational comparative-effectiveness target-trial emulation of rtCGM initiation and sustained use versus no initiation in high-risk adults with type 2 diabetes.
The analysis estimated per-protocol effects using inverse probability–weighted marginal structural models, with censoring for nonadherence, coverage gaps, death, or 36 months.
The glycemic-control finding was a durable lower HbA1c in the rtCGM arm at 36 months, about 0.8 percentage points lower than controls in the abstract-level profile.
The kidney-marker finding was a late-emerging lower UACR at 36 months, approximately −125.3 mg/g, with no significant UACR differences initially.
The eGFR finding was null: no differences in estimated glomerular filtration rate were observed during follow-up.
The observational design, residual confounding, and reliance on weighting/model assumptions limit causal interpretation.
Substantial censoring/attrition occurred, including 44.3% of rtCGM initiators censored for discontinuation and 18.7% of controls censored for initiating CGM, which may affect robustness and generalizability.
The profile distinguishes lower UACR from preserved kidney filtration function; UACR improvement did not coincide with an eGFR benefit over 36 months.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEvaluate whether initiation and sustained use of real-time continuous glucose monitoring (rtCGM) is associated with improved long-term glycemic control (HbA1c) compared with no rtCGM initiation among high-risk adults with type 2 diabetes using an emulated target trial approach.Target trial emulation; per-protocol estimation using IP-weighted marginal structural modelsExpand

In plain English

In a comparative-effectiveness emulated target trial of 25,648 high-risk adults with type 2 diabetes (2771 rtCGM initiators; 22,877 controls), sustained initiation of real-time continuous glucose monitoring (rtCGM) was associated with a durable reduction in HbA1c over 36 months. Using inverse probability–weighted marginal structural models to estimate a per-protocol effect with censoring for nonadherence, coverage gaps, death, or 36 months, rtCGM initiators had an approximately 0.8-percentage point lower HbA1c at 36 months compared with controls (rtCGM 7.83% [95% CI, 7.55%–8.11%] vs control 8.58% [95% CI, 8.49%–8.66%]; P < .001).

Key findings

Sustained initiation of rtCGM was associated with lower HbA1c over 36 months compared with no rtCGM initiation in a per-protocol, target-trial emulation.≈0.8 percentage point lower HbA1c at 36 months (rtCGM 7.83% vs control 8.58%; 95% CIs reported; P < .001).

What this piece can’t prove

Observational emulation—despite use of marginal structural models, residual confounding and bias from unmeasured variables remain possible.
High attrition and informative censoring (notably large discontinuation in rtCGM arm and CGM initiation among controls) may limit interpretability and depend on adequacy of weighting models.

1 further detail could not be confirmed from the summary.

2secondary dataEvaluate whether rtCGM initiation and sustained use is associated with improved kidney outcomes/markers (UACR and eGFR trajectories) compared with no initiation over up to 36 months in the same target trial emulation.Target trial emulation; per-protocol inverse probability–weighted marginal structural modelsExpand

In plain English

In an observational target-trial emulation of high-risk adults with type 2 diabetes, sustained real-time continuous glucose monitoring (rtCGM) initiation was associated with a later, clinically meaningful reduction in urinary albumin-creatinine ratio (UACR) by 36 months versus no CGM initiation, while there were no differences in estimated glomerular filtration rate (eGFR) over follow-up. Estimates derive from per-protocol inverse probability–weighted marginal structural models with censoring for nonadherence, coverage gaps, death, or at 36 months.

Key findings

By 36 months, rtCGM initiators had significantly lower urinary albumin-creatinine ratio (UACR) than controls.−125.3 mg/g (95% CI, −196.6 to −54.0 mg/g)
No differences in estimated glomerular filtration rate (eGFR) were observed between rtCGM initiators and controls during follow-up.

What this piece can’t prove

Substantial attrition and censoring reported (44.3% rtCGM discontinuation censoring; 18.7% control CGM initiation censoring) which may affect robustness of per-protocol estimates.
UACR difference was not present initially and only emerged by the end of 36 months.
Abstract does not report details on measurement frequency, handling of missing UACR/eGFR measurements, or other covariate measurement specifics relevant to kidney outcome ascertainment.

Finally, the search trail

Method layer